Clinical Trials

Clinical Trial
  • Status: Not yet recruiting
  • Phase: Phase 2
  • Intervention Type: Drug, Procedure
  • Participants: 70
  • Start Date: August 8, 2021
A Randomized and Placebo-Controlled Phase II Trial Targeting Dominant-Negative Missense Mutant P53 by Atorvastatin for Reducing the Risk of Longstanding Ulcerative Colitis-Associated Cancer
Clinical Trial
  • Status: Not yet recruiting
  • Intervention Type: Diagnostic Test
  • Participants: 160
  • Start Date: June 2021
The Validity of Novel Non-invasive Inflammatory Markers for Monitoring of Patients With Ulcerative Colitis
Search for trials
Clinical Trial
  • Status: Not yet recruiting
  • Phase: Phase 4
  • Intervention Type: Biological
  • Participants: 10
  • Start Date: May 1, 2021
Combination Therapy With Fecal Microbiota Transplantation and Vedolizumab for Induction of Ulcerative Colitis
Clinical Trial
  • Status: Not yet recruiting
  • Phase: Phase 4
  • Intervention Type: Drug
  • Participants: 150
  • Start Date: April 30, 2021
A Multicenter, Single-arm, Open-label, Phase 4 Study to Evaluate the Safety and Efficacy of Vedolizumab in Indian Patients With Ulcerative Colitis and Crohn's Disease
Clinical Trial
  • Status: Not yet recruiting
  • Phase: N/A
  • Intervention Type: Other
  • Participants: 48
  • Start Date: April 15, 2021
Assessing Whether Buttermilk Powder Improves Disease Activity in Pediatric IBD
Clinical Trial
  • Status: Not yet recruiting
  • Phase: N/A
  • Intervention Type: Other
  • Participants: 10
  • Start Date: April 15, 2021
Efficacy of Visceral Osteopathic Approach to Relieve Recurring Digestive Symptoms in Subjects With Inflammatory Bowel Diseases (IBS)
Clinical Trial
  • Status: Not yet recruiting
  • Participants: 400
  • Start Date: April 2021
Global IBD Visualization of Epidemiology Studies (GIVES) in the 21st Century (GIVES-21)
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 2
  • Intervention Type: Drug
  • Participants: 162
  • Start Date: April 2021
A Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects With Moderately Active Ulcerative Colitis
Showing 1-12 of 356